What is Atomwise?
Headquartered in California, Atomwise Inc. operates at the intersection of artificial intelligence and medicinal chemistry. The company utilizes deep learning to predict the binding affinity of small molecules to protein targets, effectively streamlining the traditional drug discovery process. By replacing labor-intensive laboratory screening with high-speed computational simulations, Atomwise enables pharmaceutical partners to identify promising drug candidates with greater precision and efficiency. This market position is critical as the industry shifts toward data-driven R&D models to reduce the time and cost associated with bringing new therapies to market.
How much funding has Atomwise raised?
Atomwise has raised a total of $221.6M across 7 funding rounds:
Unspecified
$225K
Other Financing Round
$120K
Angel/Seed
$6M
Series A
$45M
Series B
$123M
Grant
$2.3M
Series C
$45M
Unspecified (2013): $225K with participation from Grand Challenges Canada
Other Financing Round (2015): $120K led by David E. Weekly and Y Combinator
Angel/Seed (2015): $6M supported by Draper Fisher Jurvetson, Khosla Ventures, Data Collective, AME Cloud Ventures, and OS Fund
Series A (2018): $45M featuring B Capital Group, Baidu Ventures, Y Combinator, Data Collective, Tencent, Khosla Ventures, and Monsanto Growth Ventures
Series B (2020): $123M backed by Sanabil Investments, Y Combinator, DCVC, B Capital Group, Tencent, Dolby Family Ventures, AME Cloud Ventures, and BV
Grant (2020): $2.3M with participation from Bill & Melinda Gates Foundation
Series C (2024): $45M led by B Capital Group and Khosla Ventures
Key Investors in Atomwise
B Capital Group
B Capital is a venture capital firm that focuses on empowering entrepreneurs by investing in early and late-stage companies within the Technology, Healthcare, and Climate sectors.
Y Combinator
Established in 2005 and located in Mountain View, California, Y Combinator provides seed funding for startup businesses and to gauge investors for businesses.
Khosla Ventures
Khosla Ventures provides venture assistance and strategic advice to entrepreneurs working on breakthrough technologies, focusing on areas including AI, health, and sustainable energy.
What's next for Atomwise?
With the successful closure of its latest financing, Atomwise is well-positioned to expand its internal pipeline and enhance its collaborative research efforts. The company is expected to leverage this capital to further refine its AI models, integrate larger datasets, and potentially enter new therapeutic areas. As the firm matures, the focus will likely shift toward clinical validation of its lead candidates and the expansion of its strategic partnerships with global pharmaceutical entities. The ongoing support from top-tier venture firms suggests a long-term commitment to transforming the drug development lifecycle through technological innovation.
See full Atomwise company page
